Systemic tumor-targeting gene drive vectors proactively eliminate drug resistance in solid tumors

While targeted therapies have revolutionized cancer treatment, drug resistance remains a major barrier to their curative potential. We recently demonstrated biological proof-of-concept for selection gene drive circuits, a technology that overwrites disease evolution to proactively eliminate resistance in vivo, but translation requires a delivery method compatible with disseminated metastatic disease. Now, we demonstrate a clinically feasible delivery solution with novel tumor-targeting lentiviral vectors that selectively install these therapeutic circuits in tumor cells in situ. Systemic administration of these vectors demonstrated durable elimination of visible tumor burden and minimal body weight loss, validating the translational potential of a new class of genetic medicines for long-term control of resistance in cancer.